Description

HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1].—Cancer-Kinase/protease–C22H23N5O3—-[1]Liu Q, et al. Discovery of phthalazino [1, 2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. Eur J Med Chem. 2022, 229:114058.–2756809-34-2–405.45—-O=C(NO)CCCCCCNC(C1=C2C=CC=C1)=NN3C2=NC4=C(C=CC=C4)C3=O–Cancer–10 mM in DMSO–HDAC–HDAC1;HDAC2;HDAC3;HDAC6;HDAC8–Cell Cycle/DNA Damage;Epigenetics–Peptides